Israeli medical cannabis giant Panaxia announced in a press release on Wednesday that they have become the first company to receive regulatory approval to market an inhalable cannabis solution in Europe - Germany, more specifically - along with their strategic partner, the German pharmaceutical company Neuraxpharm.